%0 Journal Article
%T Review and analysis of history and utilization of panretinal photocoagulation and ranibizumab after publication of protocol S.
%A Shah S
%A Chou B
%A Patel M
%A Watane A
%A Shah L
%A Yannuzzi N
%A Sridhar J
%J Curr Opin Ophthalmol
%V 35
%N 5
%D 2024 Sep 1
%M 39115058
%F 4.299
%R 10.1097/ICU.0000000000001076
%X <B>OBJECTIVE: </B>We describe the history, utilization, and series results of panretinal photocoagulation (PRP) and ranibizumab and provide an analysis of PRP and ranibizumab usage before versus after the publication of the 2-year and 5-year results of the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol S trial.<BR><B>RESULTS: </B>Number of ranibizumabs performed began to increase and number of PRPs performed began to decrease in 2016. After publication of the 2-year results, there was significant negative trend in PRP services and significant positive trend in ranibizumab services (both P < 0.001). After publication of the 5-year results, there was significant negative trend in PRP services (P = 0.003). There were significant negative trends (all P < 0.001) in reimbursement factors for PRP from 2013 to 2020: average work RVU (wRVU), nonfacility physical expense RVU, facility PE RVU, malpractice RVU (MP RVU).<BR><B>CONCLUSIONS: </B>Both PRP and ranibizumab have undergone numerous trials comparing their efficacy to other treatment options or no treatment at all. The publication of the 2-year results of Protocol S was associated with an increase in utilization of ranibizumab and decrease in utilization of PRP, with continued decrease after the publication of the 5-year results.